Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Feb 12, 2014
Insider Transaction Report
Form 4
Schiller Howard Bradley
EVP and CFO
Transactions
- Exercise/Conversion
Common Stock, no par value
2014-02-11+90,000→ 312,704 total - Tax Payment
Common Stock, no par value
2014-02-11−44,855→ 267,849 total - Exercise/Conversion
Restricted Share Units
2014-02-11−90,000→ 90,000 total→ Common Stock (90,000 underlying)
Footnotes (2)
- [F1]This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $42.70 starting on December 1, 2011 and the average stock price for the 20 trading days starting on each measurement dates: 25% on September 1, 2014, 50% on December 1, 2014 and 25% on March 1, 2015. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The PSU award may still payout one time grant value.
- [F2]This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Performance Share Units.